Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

While you may think of healthcare as only covering human health, animal and pet health is also a growing sector. Click to read.

Former LEO Pharma and Bayer executive Möller stepped into the CEO role in January after the departure of Joanna Shields last ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Controlled release drug delivery market. Global Controlled Release Drug Delivery market Outlook 2024-2032: Rising Demand and Key Trends: Controlled release ...